ArticleBlood2022
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee.
Erratum issuedAbstract readConsensus Statement
In one paragraph
Article in Blood, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 871 papers, 3 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
871citing papers in PubMed, 3 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
871 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- American Society of Hematology 2026 guidelines on diagnosis of light chain amyloidosis.Blood advances · 2026Guideline
- Clinical utility of cerebrospinal fluid interleukin-10 in central nervous system lymphoma: a molecular neuropathology-informed diagnostic meta-analysis.Journal of molecular medicine (Berlin, Germany) · 2026Pooled it
- Guidelines for Diagnosis, Treatment, and Follow-Up of Patients with Follicular Lymphoma-Spanish Lymphoma Group (GELTAMO) 2025.Cancers · 2026Guideline
- Selinexor combined with R-CHOP achieved a high response rate in newly diagnosed double/triple-hit lymphoma.Blood advances · 2026Trial
- TFH phenotype and response to tucidinostat in relapsed/refractory PTCL: analysis of patients from a phase IIb trial.International journal of hematology · 2026Trial
- Clinical Flow Cytometric Testing in Chronic Lymphocytic Leukemia.Methods in molecular biology (Clifton, N.J.) · 2027Article
- Clinical outcomes, patterns of relapse, and molecular landscape of advanced stage high-grade B-cell lymphoma.Blood advances · 2026Article
- Genomic architecture of IRF4 rearrangements in childhood and adult large B-cell lymphomas.Blood advances · 2026Article
- Diagnostic challenges posed by the wide morphological and immunophenotypic spectrum of plasma cell neoplasms.Blood research · 2026Review
- Primary Cutaneous Follicular Helper T-Cell Lymphoma: A Clinicopathological Study of Six Cases and Review of the Literature.Journal of cutaneous pathology · 2026Review
- EBV-Positive Sinonasal Plasma Cell Neoplasms: A Case Series With Favorable Outcomes in Elderly Males.EJHaem · 2026Article
- Efficiency of Automated and Manual Plasma Cell Immunoselection for FISH Analysis in Multiple Myeloma.International journal of laboratory hematology · 2026Article
- Advances in molecular pathobiology of PCNSL - towards clinical implementation of novel diagnostics and therapeutics.Biomarker research · 2026Review
- Flow Cytometry-Guided Diagnosis of Cortical T-Lymphoblastic Lymphoma Presenting With a Massive Mediastinal Mass and Borderline Bone Marrow Involvement.Journal of clinical laboratory analysis · 2026Article
- Concurrent follicular lymphoma and follicular dendritic cell sarcoma: composite neoplasm or transdifferentiation?Journal of hematopathology · 2026Article
- Primary Cutaneous Lymphomas and Lymphoproliferative Disorders: Current Insights for Classification and Management.Cancers · 2026Review
- Clinicopathological Characteristics and Survival Outcomes of Male Breast Lymphoma.Journal of clinical medicine · 2026Article
- Cutaneous T Cell Lymphoma: Targeting the Survival Network in Mycosis Fungoides and Sézary Syndrome.Cancers · 2026Review
- Large B-cell lymphoma with IRF4 rearrangement: clinicopathologic heterogeneity across the age spectrum.Journal of hematopathology · 2026Article
- The Spectrum of Human Herpesvirus 8/Epstein-Barr Virus-Co-Positive Lymphoproliferations and Lymphomas.Diseases (Basel, Switzerland) · 2026Review
811 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
Authors and funding
73 authors.
Elias CampoHaematopathology Section, Hospital Clínic of Barcelona, Institut d'Investigaciones Biomèdiques August Pi I Sunyer (IDIBAPS), University of Barcelona, Centro de Investigación Biomédica en Red de Cancer (CIBERONC), Barcelona, Spain.ORCID 0000-0001-9850-9793
Elaine S JaffeHematopathology Section, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD.ORCID 0000-0003-4632-0301
James R CookPathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH.ORCID 0000-0003-0456-8085
Leticia Quintanilla-MartinezInstitute of Pathology and Neuropathology, Eberhard Karls University of Tübingen and Comprehensive Cancer Center, University Hospital Tübingen, Tübingen, Germany.ORCID 0000-0001-7156-5365
Steven H SwerdlowDepartment of Pathology, University of Pittsburgh School of Medicine, University of Pittsburgh, Pittsburgh, PA.
Kenneth C AndersonDana-Farber Cancer Institute, Boston, MA.
Pierre BroussetDepartment of Pathology, Institut Universitaire du Cancer de Toulouse-Oncopole, and Laboratoire d'Excellence Toulouse Cancer, Toulouse, France.ORCID 0000-0002-8629-3291
Lorenzo CerroniDepartment of Dermatology, Medical University of Graz, Graz, Austria.
Laurence de LevalInstitute of Pathology, Department of Laboratory Medicine and Pathology, Lausanne University Hospital and Lausanne University, Lausanne, Switzerland.
Stefan DirnhoferInstitute of Medical Genetics and Pathology, University Hospital Basel, University of Basel, Basel, Switzerland.
Ahmet DoganLaboratory of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY.ORCID 0000-0001-6576-5256
Andrew L FeldmanDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN.ORCID 0000-0001-5009-4808
Falko FendInstitute of Pathology and Neuropathology, Eberhard Karls University of Tübingen and Comprehensive Cancer Center, University Hospital Tübingen, Tübingen, Germany.
Jonathan W FriedbergWilmot Cancer Institute, University of Rochester, Rochester, NY.
Philippe GaulardDepartment of Pathology, University Hospital Henri Mondor, Assistance Publique-Hôpitaux de Paris (AP-HP), Créteil, France.
Paolo GhiaStrategic Research Program on Chronic Lymphocytic Leukemia, Division of Experimental Oncology, IRCCS Ospedale San Raffaele and Università Vita-Salute San Raffaele, Milan, Italy.ORCID 0000-0003-3750-7342
Steven M HorwitzLymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
Rebecca L KingDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN.
Gilles SallesLymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.ORCID 0000-0002-9541-8666
Jesus San-MiguelClínica Universidad de Navarra, Centro de Investigación Médica Aplicada, Instituto de Investigación Sanitaria de Navarra, CIBERONC, Pamplona, Spain.ORCID 0000-0002-9183-4857
John F SeymourPeter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, VIC, Australia.ORCID 0000-0003-2188-6835
Steven P TreonDana-Farber Cancer Institute, Boston, MA.ORCID 0000-0001-6393-6154
Julie M VoseDivision of Hematology-Oncology, Department of Internal Medicine, University of Nebraska Medical Center, University of Nebraska, Omaha, NE.ORCID 0000-0003-1015-7434
Emanuele ZuccaOncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, and Institute of Oncology Research, Università della Svizzera Italiana, Bellinzona, Switzerland.ORCID 0000-0002-5522-6109
Ranjana AdvaniStanford Cancer Center, Blood and Marrow Transplant Program, Stanford University, Stanford, CA.
Stephen AnsellDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN.
Wing-Yan AuBlood-Med Clinic, Hong Kong, People's Republic of China.
Carlos BarrionuevoDepartment of Pathology, Instituto Nacional de Enfermedades Neoplásicas, Faculty of Medicine, Universidad Nacional Mayor de San Marcos, Lima, Peru.ORCID 0000-0003-2474-914X
Leif BergsagelDivision of Hematology, Department of Internal Medicine, Mayo Clinic, Phoenix, AZ.ORCID 0000-0003-1523-7388
Wing C ChanDepartment of Pathology, City of Hope National Medical Center, Duarte, CA.
Jeffrey I CohenMedical Virology Section, Laboratory of Infectious Diseases, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Bethesda, MD.
Francesco d'AmoreDepartment of Hematology, Aarhus University Hospital, Aarhus, Denmark.
Andrew DaviesCancer Research UK Centre, Centre for Cancer Immunology, Faculty of Medicine, Southampton General Hospital, University of Southampton, Southampton, United Kingdom.ORCID 0000-0002-7517-6938
Brunangelo FaliniInstitute of Hematology and Center for Hemato-Oncology Research, Hospital of Perugia, University of Perugia , Perugia, Italy.ORCID 0000-0002-7198-5965
Irene M GhobrialDana-Farber Cancer Institute, Boston, MA.ORCID 0000-0001-7361-3092
John R GoodladNational Health Service Greater Glasgow and Clyde, Glasgow, United Kingdom.ORCID 0000-0002-8385-8517
John G GribbenDepartment of Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.ORCID 0000-0002-8505-7430
Eric D HsiDepartment of Pathology, Wake Forest School of Medicine, Wake Forest University, Winston-Salem, NC.ORCID 0000-0001-8623-4067
Brad S KahlOncology Division, Washington University School of Medicine, Washington University in St. Louis, St. Louis, MO.ORCID 0000-0003-0459-6609
Won-Seog KimHematology and Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
Shaji KumarDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN.ORCID 0000-0001-5392-9284
Ann S LaCasceDana-Farber Cancer Institute, Boston, MA.ORCID 0000-0001-7349-0176
Camille LaurentDepartment of Pathology, Institut Universitaire du Cancer de Toulouse-Oncopole, and Laboratoire d'Excellence Toulouse Cancer, Toulouse, France.
Georg LenzDepartment of Medicine A, Hematology, Oncology and Pneumology, University Hospital Muenster, Muenster, Germany.
John P LeonardWeill Department of Medicine, Weill Medical College, Cornell University, New York, NY.
Michael P LinkDepartment of Pediatrics, Division of Pediatric Hematology-Oncology, Stanford University School of Medicine, Stanford University, Stanford, CA.
Armando Lopez-GuillermoDepartment of Hematology, Hospital Clínic, IDIBAPS, University of Barcelona, Barcelona, Spain.
Maria Victoria MateosDepartment of Hematology, Hospital Universitario de Salamanca, Instituto de Investigación Biomédica de Salamanca, Centro de Investigación del Cancer, Universidad de Salamanca, Salamanca, Spain.ORCID 0000-0003-2390-1218
Elizabeth MacintyreLaboratoire d'Onco-Hématologie, AP-HP, Hôpital Necker-Enfants Malades, Université de Paris Cité and Institut Necker-Enfants Malades, Paris, France.ORCID 0000-0003-0520-0493
Ari M MelnickDivision of Hematology and Oncology, Weill Medical College, Cornell University, New York, NY.ORCID 0000-0002-8074-2287
Franck MorschhauserDepartment of Hematology, Centre Hospitalier Universitaire de Lille, University Lille, Lille, France.ORCID 0000-0002-3714-9824
Shigeo NakamuraDepartment of Pathology and Laboratory Medicine, Nagoya University Hospital, Nagoya, Japan.
Marina NarbaitzDepartment of Pathology, Instituto de Investigaciones Hematológicas, Academia Nacional de Medicina and Fundacion para combatir la leucemia (FUNDALEU), Buenos Aires, Argentina.
Astrid PavlovskyFundación para Combatir la Leucemia (FUNDALEU), Centro de Hematología Pavlovsky, Buenos Aires, Argentina.
Stefano A PileriHaematopathology Division, IRCCS, Istituto Europeo di Oncologia, Milan, Italy.ORCID 0000-0001-8032-5128
Miguel PirisJiménez Díaz Foundation University Hospital, Universidad Autónoma de Madrid, Madrid, Spain.ORCID 0000-0001-5839-3634
Barbara ProDivision of Hematology and Oncology, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL.
Vincent RajkumarDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN.
Steven T RosenBeckman Research Institute, and Department of Hematology & Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA.
Birgitta SanderDepartment of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden.
Laurie SehnCentre for Lymphoid Cancer, British Columbia Cancer Agency, Vancouver, BC, Canada.
Margaret A ShippDana-Farber Cancer Institute, Boston, MA.ORCID 0000-0002-3949-6897
Sonali M SmithSection of Hematology/Oncology, University of Chicago, Chicago, IL.ORCID 0000-0002-9893-4949
Louis M StaudtLymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD.
Catherine ThieblemontService Hémato-Oncologie, AP-HP, Hôpital Saint-Louis, Paris, France.
Thomas TousseynDepartment of Pathology, Universitair Ziekenhuis Leuven Hospitals, Leuven, Belgium.
Wyndham H WilsonLymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD.
Tadashi YoshinoDepartment of Pathology, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University, Okayama, Japan.
Pier-Luigi ZinzaniAzienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seragnoli", Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Bologna, Italy.ORCID 0000-0002-2112-2651
Martin DreylingDepartment of Medicine III, Ludwig-Maximilians-University Hospital, Munich, Germany.ORCID 0000-0002-0358-5249
David W ScottCentre for Lymphoid Cancer, British Columbia Cancer Agency, Vancouver, BC, Canada.ORCID 0000-0002-0435-5947
Jane N WinterFeinberg School of Medicine, Northwestern University, Chicago, IL; and.
Andrew D ZelenetzLymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.ORCID 0000-0003-1403-6883
Funding
Molecular diagnosis and outcome prediction in lymphomaZIABC011006 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI STAUDT, LOUIS · 2009 to 2025
$21.0MLymphoma Disease Discovery and DefintionZIASC000550 · NCI · DIVISION OF CLINICAL SCIENCES - NCI · PI JAFFE, ELAINE · 2009 to 2025
$16.9MClinical development of mechanism-based lymphoma therapiesZIABC011780 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI STAUDT, LOUIS · 2017 to 2025
$11.4MTherapeutic Strategies and Molecular Correlates in Aggressive B-cell LymphomasZIASC006741 · NCI · DIVISION OF CLINICAL SCIENCES - NCI · PI WILSON, WYNDHAM H · 2009 to 2025
$10.4MPathogenesis and Chemotherapy of Human Virus InfectionsZIAAI000058 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI COHEN, JEFFREY · 2009 to 2025
$8.8MTargeted treatment of B-cell LymphomaZIABC011354 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI WILSON, WYNDHAM H · 2010 to 2025
$4.6MIntramural NIH HHS ZIA AI000058Intramural NIH HHS ZIA BC011780Intramural NIH HHS ZIA SC000550
Abstract
Since the publication of the Revised European-American Classification of Lymphoid Neoplasms in 1994, subsequent updates of the classification of lymphoid neoplasms have been generated through iterative international efforts to achieve broad consensus among hematopathologists, geneticists, molecular scientists, and clinicians. Significant progress has recently been made in the characterization of malignancies of the immune system, with many new insights provided by genomic studies. They have led to this proposal. We have followed the same process that was successfully used for the third and fourth editions of the World Health Organization Classification of Hematologic Neoplasms. The definition, recommended studies, and criteria for the diagnosis of many entities have been extensively refined. Some categories considered provisional have now been upgraded to definite entities. Terminology for some diseases has been revised to adapt nomenclature to the current knowledge of their biology, but these modifications have been restricted to well-justified situations. Major findings from recent genomic studies have impacted the conceptual framework and diagnostic criteria for many disease entities. These changes will have an impact on optimal clinical management. The conclusions of this work are summarized in this report as the proposed International Consensus Classification of mature lymphoid, histiocytic, and dendritic cell tumors.
Indexed as
Hematologic NeoplasmsLymphomaAdvisory CommitteesHumansWorld Health Organization
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.